



Bundesamt für  
Verbraucherschutz und  
Lebensmittelsicherheit



# **CIR (EU) 2021/808**

Changes to Revision CD 2002/657 EC

## COMMISSION IMPLEMENTING REGULATION (EU) 2021/808

of 22 March 2021

**on the performance of analytical methods for residues of pharmacologically active substances used in food-producing animals and on the interpretation of results as well as on the methods to be used for sampling and repealing Decisions 2002/657/EC and 98/179/EC**

(Text with EEA relevance)

2021

2015

## Keeping proven principles

(criteria approach, concept of identification points, concept of decision limit and detection capability)

## Consideration of technical progress

(mass spectrometry, chromatography)

## Consideration of guidelines in addition to 2002/657

(“SANCO/2004/2726”, “screening guideline”)

## Consideration of ISO 17025:2017 requirements

## Reference to practical EURL guidance

## CIR (EU) 2021/808 (Rev. Decision 2002/657 EC)

### “Legal part”

Article 1 - Subject matter and scope

Article 2 - **Definitions**

Article 3 - Methods of analysis

Article 4 - Quality control

*reference to ISO 17025*

Article 5 - **Interpretation of results**

Article 6 - Methods for sampling

*former Decision 98/179/EC*

Article 7 - Repeals and transitional measures

*old data valid until 2026 !!*

Article 8 - Entry into force

*10 June 2021 !!*

### “Technical part”

**ANNEX I**

***details on methods and validation***

**ANNEX II**

*sampling*

## Article 5 - Interpretation of results

The result of an analysis shall be considered **non-compliant** where it is equal to or above the decision limit for confirmation (**CC $\alpha$** ).

## Article 2 – Definitions

### MRL or ML substances:

the CC $\alpha$  shall be the concentration at and above which it can be decided with a statistical certainty of  $1 - \alpha$  that the permitted limit has been exceeded.

**(the  $\alpha$  error shall be 5 % or lower)**

### Unauthorised or prohibited substances:

CC $\alpha$  shall be **the lowest concentration level** at which it can be decided with a statistical certainty of  $1 - \alpha$  that the particular analyte is present.

**(the  $\alpha$  error shall be 1 % or lower)**

## Article 2 – Definitions

**level of interest** means the concentration of a substance in a sample that is **significant to determine its compliance** with the legislation as regards:

- MRLs and MLs (CR 124/2009 + CR 37/2010+ ...)
- RPAs (Regulation (EU) 2019/1871)
- a concentration **as low as analytically achievable** for prohibited or unauthorised substance (no RPA present)

**=> new MMPR guidance**

**(Minimum method performance Requirements)**

## Article 2 - Definitions

**detection capability for screening (CC $\beta$ )** means the (smallest) content of the analyte that may be detected or quantified in a sample with an error probability of  $\beta$  (the  $\beta$  error shall be 5 % or lower) :

### prohibited or unauthorised substances:


CC $\beta$  is the lowest concentration at which a method is able to detect or quantify with a statistical certainty of  $1 - \beta$ , samples containing residues of prohibited or unauthorised substances;

### authorised substances

CC $\beta$  is the concentration at which the method is able to detect concentrations below the permitted limit with a statistical certainty of  $1 - \beta$ ;

## Decision limit

For confirmatory methods




Evaluation of **a sample** !

$$\begin{aligned}
 CC_\alpha &> MRL / ML \\
 &\leq RPA, < MMPR
 \end{aligned}$$

False non-compliant decision, i.e. even though the concentration is truly compliant, the result is non compliant

## Detection capability

For screening methods



Evaluation of **a method** !

$$STC \leq CC_\beta < MRL, ML \text{ or } RPA / MMPR$$

False compliant result, i.e. the sample is **not send to confirmation**, even though the concentration is truly at the  $CC_\beta$



## Article 2 - Definitions

“Rules” for results of screening methods with regard the interpretation of results:

**screening target concentration (STC)** means the concentration **lower than or equal to the CC $\beta$**  at which a screening measurement categorises the sample as potentially non-compliant ‘Screen Positive’ and **triggers a confirmatory testing**

**lowest calibrated level (LCL)** means the lowest concentration on which the measuring system has been calibrated

“lowest spike level which can be reliably detected”

(the concentration at which the analyte can be confirmed in at least 50 % of the cases )

## Annexes

### Annex 1 : Methods Requirements

Chapter 1: **Performance criteria and other requirements for analytical methods**

Chapter 2: **Validation**

Chapter 3: QC during routine analysis – ongoing method performance verification

Chapter 4: Extension of the validated scope of a previously validated method via quality control samples during routine analysis

### Annex 2 : Sampling procedures and official sample treatment

## Chapter 1: Performance criteria and other requirements for analytical methods

### 1.1 Requirements of screening methods

#### 1.1.1 Categories of suitable screening methods

Qualitative, semi-quantitative or quantitative methods

#### 1.1.2 Requirements for biological, biochemical or physico-chemical screening methods

CC $\beta$  screening shall be as low as analytically achievable

i.e. lower than MRL/ML/RPA/MMPR

**false compliant rate is lower than or equal to 5% ( $\beta$ -error)**

(validated methods / demonstrated in a documented traceable manner)

**= > Introduction of STC**

## Chapter 1:

### 1.2 Requirements of confirmatory methods

#### 1.2.1 General requirements of confirmatory methods

prohibited or unauthorised substances:

the CC $\alpha$  shall be **as low as analytically achievable**

CC $\alpha$  shall be lower than or equal to the RPA / **lower than MMPR**

For MRL substances the CC $\alpha$  shall be higher than but **as close as possible**  
to the MRL or ML.

false non-compliant rate ( $\alpha$ -error)

less or equal to 1% for prohibited or unauthorised substances

less or equal to 5% for MRL substances

(validated methods / demonstrated in a documented traceable manner)

## Chapter 1:

### 1.2 Requirements of confirmatory methods


#### 1.2.1 General requirements of confirmatory methods

usually : MS-based methods

In the case of mass spectrometry not being suitable **for registered veterinary substances**, also other methods like e.g. **HPLC-DAD-FLD**

e.g.

Avermectin B1a bzw.  
8,9-Z-Avermectin B1a  
und  
Avermectin B1b



## 1.2 Requirements of confirmatory methods

### 1.2.2 General performance criteria for confirmatory methods

minor changes : Minimum **trueness** of quantitative methods

Mass Fraction	Range
≤ 1 µg/kg	-50 % to +20 %
> 1 µg/kg to 10 µg/kg	-30 % to +20 %
≥ 10 µg/kg	-20 % to +20 %

minor changes: Acceptable coefficient of variation (**precision**) :

Mass fraction	Reproducibility CV (%)
> 1 000 µg/kg	16 (adapted from Horwitz equation)
> 120 µg/kg – 1 000 µg/kg	22 (adapted from Horwitz equation)
10 – 120 µg/kg	25 (*)
< 10 µg/kg	30 (*)

\*) the CV is a **guideline** and should be as low as reasonably possible

**repeatability** conditions shall be equal or below two thirds of the table values

## 1.2.3. Requirements for chromatographic separation

the minimum acceptable retention time for the analyte(s) shall be twice the void volume retention time

The retention time of the analyte in the extract shall correspond to that of the ... standard (matrix, matrix matches, solution) ...

- with a tolerance **of  $\pm 0.1$  minute** or
- a deviation of less than 5% of the retention time, in case the retention time is below 2 minutes.

In case an **internal standard** is used, the **relative retention time** of the analyte, shall correspond to that of the ... standard ...(matrix, matrix matches, solution)

- with a maximum deviation 0.5 % for gas chromatography and
- **1 % for liquid chromatography** for methods.

## 1.2.4 Specific performance criteria for mass spectrometry

### Definition HRMS

the **mass deviation** of all diagnostic ions shall be **below 5 ppm** (or in case of  $m/z < 200$  below 1 mDa). Resolution shall typically be greater than 10,000 for the entire mass range at 10 % valley or **20,000 at full width at half maximum** (FHWM).

The selected fragment or product ions shall be diagnostic.... Non-selective transitions (e.g. the tropylium cation or loss of water) shall be omitted whenever possible.

For all mass spectrometric analyses **at least one ion ratio** shall be determined.

**The ion ratio** of the analyte to be confirmed shall correspond to those of the matrix-matched standards, matrix-fortified standards or standard solutions at comparable concentrations, measured under the same conditions, within  **$\pm 40$  % relative deviation**.



## 1.2.3.3 Identification (identification points)

### Identification points per technique

Technique	Identification Points
Separation (mode GC, LC, SFC, CE)	1
LR-MS ion	1
Precursor ion selection at $<\pm 0,5$ Da mass range	1 (indirect)
LR-MS <sub>n</sub> product ion	1,5
HR-MS ion	1,5
HR-MS <sub>n</sub> product ion	2,5

MRL substances : a minimum of **4 identification points**

non-authorized or prohibited substances:

a minimum of **5 identification points**

One point can originate from the **chromatographic separation**

# Summary of important Changes

## Performance characteristic Changes from CD 2002/657 to CIR 2021/808

<b>Identification</b>	Change in the concept for the identification points	ion ratios ! (+/- 40 % in general) HRMS definition for mass accuracy One IP for chromatographic separation
<b>Chromatography</b>	General requirements for validation remain the same, requirements for identification (RT time) have been adjusted	New: absolute RT time criteria LC : permitted relative retention time deviation reduced to 1 %

## 2.1 Performance characteristics to be determined for analytical methods

Method	Confirmation		Screening		
	Qualitative	Quantitative	Qualitative	Semi-quantitative	Quantitative
Substances	A	A, B	A, B	A, B	A, B
Identification in accordance with 1.2	x	x			
CC $\alpha$	x	x			
CC $\beta$	-	-	x	x	x
Trueness		x			x
Precision		x		(x)	x
Relative matrix effect/absolute recovery (*)		x			x
Selectivity/ Specificity		x	x	x	x
Stability (#)		x	x	x	x
Ruggedness		x	x	x	x

Quantitative methods can be "downgraded" and defined as e.g. qualitative or semiquantitative

## 2.2 Trueness, repeatability and within-laboratory reproducibility

Legal limit	CD 2002/657	CIR 2021/808
MRL/ML	0.5, 1.0, 1.5 MRL/ML	<b>0.1</b> (0.5), 1.0, 1.5 MRL/ML
MRPL	1.0, 1.5, 2.0 MRPL	MRPL concept has been revoked
RPA	-	0.5 (1.0), 1.0, 1.5 <b>RPA</b>
MMPR	Concept first introduced in connection with CIR 2021/808	Analytical methods <b>need to be validated below MMPR</b> , fortification levels can be similar to those for RPA compounds
Unauthorised compound		1.0, 2.0, 3.0 LCL

6 repetitions each – done at three different occasions (repeatability / within- lab reproducibility)

### Remarks :

#### 1) If reasonably achievable !!! - otherwise:

- the lowest concentration between 0,5 times and 1,0 times the RPA
- the lowest concentration between 0,1 times and 0,5 times the MRL

#### 2) If techniques allow to analyse substances below 0.5 times the RPA do so – => Anyhow the RPA itself should be one concentration level

## Chapter 2.6 / 2.7 : $CC_{\alpha}$ and $CC_{\beta}$

### Measurement uncertainty

“For the control of the compliance of samples, the combined standard measurement uncertainty has already been taken into account in the  $CC_{\alpha}$  value (decision limit for confirmation)”

**= decision rule**

“The within-laboratory reproducibility and the trueness are suitable to define the (combined) standard measurement uncertainty, if determined by taking into account all relevant influencing factors.”

## New working Item proposal



The screenshot shows the top navigation bar of the ISO website with links for Standards, About us, News, Taking part, Store, and EN. Below the navigation bar is the ISO logo, followed by the title **ISO/WD TS 23471** and the subtitle **EXPERIMENTAL DESIGNS FOR EVALUATION OF UNCERTAINTY — USE OF FACTORIAL DESIGNS FOR DETERMINING UNCERTAINTY FUNCTIONS**.

- 1 Scope
- 2 Normative references / 3 Terms and definitions 4 Symbols
- 5 General principles
- 5.1 General
- 5.2 Principles of **conventional approach**
- 5.3 Principles of **factorial approach**
- 6 Blocking approach
- 7 Factorial approach


## CC $\alpha$ (banned) : (three) possible calculation methods

### Method 1: by the calibration curve procedure according to ISO 11843-1:1997

...blank material shall be used, which is fortified at and above the RPA or LCL in equidistant steps...

### Method 3: $CC\alpha = LCL + k(\text{one-sided, 99 \%}) \times (\text{combined}) \text{ standard measurement uncertainty at LCL}$

...calibration curves from 8 runs + confidence interval ...



### CC $\alpha$ (banned) continued

*Method 2: by analysing at least 20 representative blank materials per matrix to be able to calculate the signal to noise ratio*

1+2 shall be verified by analysing blank matrix fortified at the calculated decision limit ; 2 : transition period for old validations until end 2025

### CC $\alpha$ (MRL/ML)

comparable to banned substances, but use of MRL/ML levels for calculation

For authorised substances in matrix/species combinations for which no MRL has been set, **no residues** shall be present



**Sum-MRL** : the CC $\alpha$  of the substance with the highest concentration in the sample shall be used as the CC $\alpha$

### Examples:

Thiabendazol: MRL : sum of thiabendazole and hydroxy-thiabendazol.  
MRL in muscle is **100  $\mu\text{g}/\text{kg}$** .

Validation: thiabendazole (spike: 100  $\mu\text{g}/\text{kg}$ , **CC $\alpha$  : 109  $\mu\text{g}/\text{kg}$** ) ,  
hydroxy-thiabendazole (spike: 100  $\mu\text{g}/\text{kg}$ , **CC $\alpha$  : 116  $\mu\text{g}/\text{kg}$** )

Sample 1 : thiabendazole: 20  $\mu\text{g}/\text{kg}$  + hydroxy-thiabendazole: 70  $\mu\text{g}/\text{kg}$   
=> sum is **90  $\mu\text{g}/\text{kg}$**  => **compliant**;

Sample 2 : containing thiabendazole: 40  $\mu\text{g}/\text{kg}$  + hydroxy-thiabendazole: 80  $\mu\text{g}/\text{kg}$   
=> sum is **120  $\mu\text{g}/\text{kg}$**  => **non compliant**

**= > take into account the CC $\alpha$  (at the MRL level ! ) for the substance with the highest concentration**

i.e. here hydroxy-thiabendazole with a CC $\alpha$ : 116  $\mu\text{g}/\text{kg}$


## CC $\beta$ : three possible calculation methods

### Method 1: by the calibration curve procedure according to ISO 11843-1:1997

...material fortified at and below the RPA (if no RPA around the STC) in equidistant steps...

### Method 3: CC $\beta$ = STC + k(one-sided, 95 %) $\times$ (combined) standard measurement uncertainty above the STC

...calculate the maximum STC for control of a given level of interest ...




## CC $\beta$ continued

**Method 2: fortified blank material at concentration levels at and above the STC. The level, where only  $\leq 5\%$  false compliant results remain, equals CC $\beta$**

Counting experiment /  
Theoretical example

i.e. at concentration  
levels  $> „6“$   
 $\leq 5\%$  false compliant  
results remain

100 experiments at each concentration (1 – 13 )  
Number of „negative“ results / number of „positive“ results



# Summary of Changes

## Performance characteristic Changes from CD 2002/657 to CIR 2021/808

<b>Concentrations levels/ranges</b>	Levels/ranges which should be validated have been revised	lower starting points (if reasonably achievable)
<b>Precision</b>	Acceptable coefficients of variation have been revised	more generously
<b>Trueness</b>	Acceptable ranges for analyte mass fractions >1 µg/kg have been revised	more generously
<b>CC<math>\alpha</math></b>	Additional calculation method	Inclusion of the MU
<b>CC<math>\beta</math></b>	Change of the concept of the CC $\beta$	only of interest for screening !
<b>Measurement uncertainty</b>	Not explicitly mentioned in CD 2002/657	example of interpretation is provided
<b>Relative matrix effect</b>	Not explicitly mentioned in CD 2002/657	to be determined either separately or as part of the validation scheme
<b>Absolute recovery</b>	Previously referred to as “recovery”	t.b.d. if no internal standard is used
<b>Calibration curve</b>	No changes in the requirements	
<b>Specificity / selectivity</b>	No changes in the requirements	
<b>Stability</b>	No change in the requirements	
<b>Ruggedness</b>	No changes, but less detailed	

# Thank you for your attention!

**Contact:**

[eurlvetdrug@bvl.bund.de](mailto:eurlvetdrug@bvl.bund.de)

[www.eurl-residues.eu](http://www.eurl-residues.eu)